Ted M Dawson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5486853/publications.pdf

Version: 2024-02-01

401
papers

77,826
citations

419

132
h-index

529

266
g-index

472
all docs

472
docs citations

472
times ranked

66876
citing authors

#	Article	IF	Citations
1	CYFIP1 Dosages Exhibit Divergent Behavioral Impact via Diametric Regulation of NMDA Receptor Complex Translation in Mouse Models of Psychiatric Disorders. Biological Psychiatry, 2022, 92, 815-826.	1.3	8
2	ADPâ€ribosyltransferases, an update on function and nomenclature. FEBS Journal, 2022, 289, 7399-7410.	4.7	150
3	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. Brain, 2022, 145, 1757-1762.	7.6	17
4	Interleukin-6 triggers toxic neuronal iron sequestration in response to pathological Î±-synuclein. Cell Reports, 2022, 38, 110358.	6.4	18
5	Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver. IScience, 2022, 25, 103996.	4.1	19
6	Deubiquitinase CYLD acts as a negative regulator of dopamine neuron survival in Parkinsonâ€™s disease. Science Advances, 2022, 8, eabh1824.	10.3	12
7	STING mediates neurodegeneration and neuroinflammation in nigrostriatal Î±-synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2118819119.	7.1	64
8	A high-affinity cocaine binding site associated with the brain acid soluble protein 1. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2200545119.	7.1	2
9	Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease. Movement Disorders, 2022, 37, 1454-1464.	3.9	13
10	PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinsonâ€™s disease. Cell, 2022, 185, 1943-1959.e21.	28.9	36
11	Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinsonâ€™s disease. Neuron, 2022, 110, 2422-2437.e9.	8.1	64
12	Nanozyme scavenging ROS for prevention of pathologic Î±-synuclein transmission in Parkinsonâ€™s disease. Nano Today, 2021, 36, 101027.	11.9	78
13	Brainstem Pathologies Correlate With Depression and Psychosis in Parkinson's Disease. American Journal of Geriatric Psychiatry, 2021, 29, 958-968.	1.2	17
14	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
15	Lymphocyte Activation Gene 3 (Lag3) Contributes to Î±-Synucleinopathy in Î±-Synuclein Transgenic Mice. Frontiers in Cellular Neuroscience, 2021, 15, 656426.	3.7	29
16	Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease. JAMA Neurology, 2021, 78, 312.	9.0	83
17	The cell biology of Parkinsonâ€™s disease. Journal of Cell Biology, 2021, 220, .	5.2	77
18	AIF3 splicing switch triggers neurodegeneration. Molecular Neurodegeneration, 2021, 16, 25.	10.8	3

#	ARTICLE	IF	CITATIONS
19	Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2021, 9, 78.	5.2	82
20	Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 469-480.	1.3	10
21	Targeting Parthanatos in Ischemic Stroke. Frontiers in Neurology, 2021, 12, 662034.	2.4	28
22	Protocol for measurement of calcium dysregulation in human induced pluripotent stem cell-derived dopaminergic neurons. STAR Protocols, 2021, 2, 100405.	1.2	7
23	Mechanistic basis for receptor-mediated pathological Î±-synuclein fibril cell-to-cell transmission in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	59
24	Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. ELife, 2021, 10, .	6.0	15
25	Complement and Coagulation Cascades are Potentially Involved in Dopaminergic Neurodegeneration in Î±-Synuclein-Based Mouse Models of Parkinsonâ€™s Disease. Journal of Proteome Research, 2021, 20, 3428-3443.	3.7	21
26	Neurodegenerative disorders and gut-brain interactions. Journal of Clinical Investigation, 2021, 131, .	8.2	55
27	Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis. Neurotherapeutics, 2021, 18, 1834-1848.	4.4	11
28	PARIS farnesylation prevents neurodegeneration in models of Parkinsonâ€™s disease. Science Translational Medicine, 2021, 13, .	12.4	30
29	Seeking progress in disease modification in Parkinson disease. Parkinsonism and Related Disorders, 2021, 90, 134-141.	2.2	9
30	Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration. Brain, 2021, 144, 3674-3691.	7.6	13
31	LRRK2 Modulates the Exocyst Complex Assembly by Interacting with Sec8. Cells, 2021, 10, 203.	4.1	1
32	USP39 promotes non-homologous end-joining repair by poly(ADP-ribose)-induced liquid demixing. Nucleic Acids Research, 2021, 49, 11083-11102.	14.5	12
33	Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. Pharmacological Reviews, 2021, 73, 1204-1268.	16.0	11
34	TRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinsonâ€™s disease. Neuron, 2021, 109, 3758-3774.e11.	8.1	26
35	Waiting for PARISâ€”A Biological Target in Search of a Drug. Journal of Parkinson's Disease, 2021, , 1-9.	2.8	2
36	Integrative genome-wide analysis of dopaminergic neuron-specific PARIS expression in Drosophila dissects recognition of multiple PPAR-Î³ associated gene regulation. Scientific Reports, 2021, 11, 21500.	3.3	8

#	ARTICLE	IF	CITATIONS
37	Dysregulated mRNA Translation in the G2019S LRRK2 and LRRK2 Knock-Out Mouse Brains. ENeuro, 2021, 8, ENEURO.0310-21.2021.	1.9	6
38	Recent advances in preventing neurodegenerative diseases. Faculty Reviews, 2021, 10, 81.	3.9	4
39	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149
40	Defects in mRNA Translation in LRRK2-Mutant hiPSC-Derived Dopaminergic Neurons Lead to Dysregulated Calcium Homeostasis. Cell Stem Cell, 2020, 27, 633-645.e7.	11.1	38
41	Meta-Analysis of the Alzheimerâ€™s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Reports, 2020, 32, 107908.	6.4	199
42	Determinants of seeding and spreading of Î±-synuclein pathology in the brain. Science Advances, 2020, 6, .	10.3	61
43	Microglia and astrocyte dysfunction in parkinson's disease. Neurobiology of Disease, 2020, 144, 105028.	4.4	177
44	Molecular Mediation of Prion-like Î±-Synuclein Fibrillation from Toxic PFFs to Nontoxic Species. ACS Applied Bio Materials, 2020, 3, 6096-6102.	4.6	8
45	Defects in Mitochondrial Biogenesis Drive Mitochondrial Alterations in PARKIN-Deficient Human Dopamine Neurons. Stem Cell Reports, 2020, 15, 629-645.	4.8	48
46	AMPA Receptor Surface Expression Is Regulated by S-Nitrosylation of Thorase and Transnitrosylation of NSF. Cell Reports, 2020, 33, 108329.	6.4	12
47	Development of a novel method for the quantification of tyrosine 39 phosphorylated Î±- and Î²-synuclein in human cerebrospinal fluid. Clinical Proteomics, 2020, 17, 13.	2.1	10
48	Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases. International Review of Cell and Molecular Biology, 2020, 353, 1-29.	3.2	63
49	PARIS induced defects in mitochondrial biogenesis drive dopamine neuron loss under conditions of parkin or PINK1 deficiency. Molecular Neurodegeneration, 2020, 15, 17.	10.8	58
50	PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2020, 15, 20.	10.8	264
51	Quantitative mass spectrometric analysis of the mouse cerebral cortex after ischemic stroke. PLoS ONE, 2020, 15, e0231978.	2.5	11
52	NLRP3 inflammasome activation in dopamine neurons contributes to neurodegeneration in Parkinsonâ€™s Disease. FASEB Journal, 2020, 34, 1-1.	0.5	6
53	Integration of Human Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons into Rat Brain. Bio-protocol, 2020, 10, e3746.	0.4	2
54	Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications, 2019, 7, 125.	5.2	47

#	ARTICLE	IF	CITATIONS
55	SQSTM1/p62 promotes mitochondrial ubiquitination independently of PINK1 and PRKN/parkin in mitophagy. Autophagy, 2019, 15, 2012-2018.	9.1	93
56	Transneuronal Propagation of Pathologic Î±-Synuclein from the Gut to the Brain Models Parkinsonâ€™s Disease. Neuron, 2019, 103, 627-641.e7.	8.1	830
57	Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinsonâ€™s disease. Brain, 2019, 142, 2380-2401.	7.6	46
58	The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration. Movement Disorders, 2019, 34, 959-969.	3.9	68
59	Fyn kinase regulates misfolded Î±-synuclein uptake and NLRP3 inflammasome activation in microglia. Journal of Experimental Medicine, 2019, 216, 1411-1430.	8.5	169
60	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
61	Assessment of APOE in atypical parkinsonism syndromes. Neurobiology of Disease, 2019, 127, 142-146.	4.4	21
62	Neurons Derived from Human Induced Pluripotent Stem Cells Integrate into Rat Brain Circuits and Maintain Both Excitatory and Inhibitory Synaptic Activities. ENeuro, 2019, 6, ENEURO.0148-19.2019.	1.9	16
63	Promising disease-modifying therapies for Parkinsonâ€™s disease. Science Translational Medicine, 2019, 11, .	12.4	46
64	Genetic analysis of neurodegenerative diseases in a pathology cohort. Neurobiology of Aging, 2019, 76, 214.e1-214.e9.	3.1	25
65	Synthetic mRNAs Drive Highly Efficient iPS Cell Differentiation to Dopaminergic Neurons. Stem Cells Translational Medicine, 2019, 8, 112-123.	3.3	39
66	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
67	The AAAâ€‰+â€‰ATPase Thorase is neuroprotective against ischemic injury. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1836-1848.	4.3	10
68	Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 29-36.	2.2	94
69	Nitric Oxide Signaling in Neurodegeneration and Cell Death. Advances in Pharmacology, 2018, 82, 57-83.	2.0	65
70	DISC1 regulates lactate metabolism in astrocytes: implications for psychiatric disorders. Translational Psychiatry, 2018, 8, 76.	4.8	34
71	A homozygous ATAD1 mutation impairs postsynaptic AMPA receptor trafficking and causes a lethal encephalopathy. Brain, 2018, 141, 651-661.	7.6	52
72	Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1635-1640.	7.1	70

#	ARTICLE	IF	CITATIONS
73	Pathological Endogenous Î±-Synuclein Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in Multiple System Atrophy. Stem Cell Reports, 2018, 10, 356-365.	4.8	61
74	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 2018, 25, 486-541.	11.2	4,036
75	GBA1 deficiency negatively affects physiological Î±-synuclein tetramers and related multimers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 798-803.	7.1	139
76	Opportunities for the repurposing of PARP inhibitors for the therapy of nonâ€oncological diseases. British Journal of Pharmacology, 2018, 175, 192-222.	5.4	160
77	Domainâ€specific cognitive impairment in nonâ€demented Parkinson's disease psychosis. International Journal of Geriatric Psychiatry, 2018, 33, e131-e139.	2.7	9
78	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism and Related Disorders, 2018, 47, 50-56.	2.2	14
79	Onset and Remission of Psychosis in Parkinson's Disease: Pharmacologic and Motoric Markers. Movement Disorders Clinical Practice, 2018, 5, 31-38.	1.5	9
80	Animal models of neurodegenerative diseases. Nature Neuroscience, 2018, 21, 1370-1379.	14.8	358
81	Poly(ADP-ribose) drives pathologic Î±-synuclein neurodegeneration in Parkinsonâ€™s disease. Science, 2018, 362, .	12.6	317
82	The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change. Juntendo Medical Journal, 2018, 64, 17-30.	0.1	0
83	Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism and Related Disorders, 2018, 53, 108-109.	2.2	1
84	Reply: ATAD1 encephalopathy and stiff baby syndrome: a recognizable clinical presentation. Brain, 2018, 141, e50-e50.	7.6	1
85	Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease. Cell Metabolism, 2018, 28, 588-604.e5.	16.2	180
86	Î±-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism. Molecular Neurodegeneration, 2018, 13, 1.	10.8	143
87	Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration. Molecular Neurodegeneration, 2018, 13, 8.	10.8	87
88	Finding useful biomarkers for Parkinsonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	125
89	Dopamine transporter availability reflects gastrointestinal dysautonomia in early Parkinson disease. Parkinsonism and Related Disorders, 2018, 55, 8-14.	2.2	37
90	Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinsonâ€™s disease. Nature Medicine, 2018, 24, 931-938.	30.7	712

#	ARTICLE	IF	CITATIONS
91	Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 2017, 541, 481-487.	27.8	4,977
92	Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics. Annual Review of Pharmacology and Toxicology, 2017, 57, 437-454.	9.4	120
93	PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. Cell Reports, 2017, 18, 918-932.	6.4	141
94	Precision therapy for a new disorder of AMPA receptor recycling due to mutations in <i>ATAD1</i>. Neurology: Genetics, 2017, 3, e130.	1.9	40
95	The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Molecular Neurodegeneration, 2017, 12, 32.	10.8	62
96	Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes. Experimental Neurology, 2017, 298, 191-201.	4.1	55
97	Prediction of cognition in Parkinson's disease with a clinicalâ€“genetic score: a longitudinal analysis of nine cohorts. Lancet Neurology, The, 2017, 16, 620-629.	10.2	131
98	T cells from patients with Parkinsonâ€™s disease recognize Î±-synuclein peptides. Nature, 2017, 546, 656-661.	27.8	618
99	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. Brain, 2017, 140, e33-e33.	7.6	2
100	Models of LRRK2-Associated Parkinsonâ€™s Disease. Advances in Neurobiology, 2017, 14, 163-191.	1.8	50
101	Activation mechanisms of the E3 ubiquitin ligase parkin. Biochemical Journal, 2017, 474, 3075-3086.	3.7	47
102	Toward the human cellular microRNAome. Genome Research, 2017, 27, 1769-1781.	5.5	142
103	Thorase variants are associated with defects in glutamatergic neurotransmission that can be rescued by Perampanel. Science Translational Medicine, 2017, 9, .	12.4	20
104	Two approaches reveal a new paradigm of â€˜switchable or genetics-influenced allele-specific DNA methylationâ€™ with potential in human disease. Cell Discovery, 2017, 3, 17038.	6.7	25
105	Cell Death Mechanisms of Neurodegeneration. Advances in Neurobiology, 2017, 15, 403-425.	1.8	90
106	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomarkers in Medicine, 2017, 11, 451-473.	1.4	49
107	Heterozygous PINK1 p.G411S increases risk of Parkinsonâ€™s disease via a dominant-negative mechanism. Brain, 2017, 140, 98-117.	7.6	116
108	Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 1982-1993.	4.3	20

#	ARTICLE	IF	CITATIONS
109	c-Abl and Parkinsonâ€™s Disease: Mechanisms and Therapeutic Potential. Journal of Parkinson's Disease, 2017, 7, 589-601.	2.8	67
110	Overexpression of Parkinsonâ€™s Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and Î±-Synuclein Pathology. ENeuro, 2017, 4, ENEURO.0004-17.2017.	1.9	31
111	The NINDS Parkinson's disease biomarkers program. Movement Disorders, 2016, 31, 915-923.	3.9	83
112	LRRK2 G2019S transgenic mice display increased susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-mediated neurotoxicity. Journal of Chemical Neuroanatomy, 2016, 76, 90-97.	2.1	36
113	Pathological Î±-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science, 2016, 353, .	12.6	521
114	Cognitive impairment in Parkinson's disease: Association between patient-reported and clinically measured outcomes. Parkinsonism and Related Disorders, 2016, 33, 107-114.	2.2	21
115	Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. Parkinsonism and Related Disorders, 2016, 33, 102-106.	2.2	8
116	A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science, 2016, 354, .	12.6	266
117	LRRK2 pathobiology in Parkinson's disease â€“ virtual inclusion. Journal of Neurochemistry, 2016, 139, 75-76.	3.9	5
118	Association of<i>GBA</i>Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217.	9.0	185
119	Ubiquitination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1. Nature Communications, 2016, 7, 11792.	12.8	56
120	Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity. Science Translational Medicine, 2016, 8, 333ra48.	12.4	66
121	<i>C9orf72</i> Hexanucleotide Repeat Analysis in Cases with Pathologically Confirmed Dementia with Lewy Bodies. Neurodegenerative Diseases, 2016, 16, 370-372.	1.4	8
122	Next-generation sequencing reveals substantial genetic contribution to dementia with Lewy bodies. Neurobiology of Disease, 2016, 94, 55-62.	4.4	55
123	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
124	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in <scp>P</scp>arkinson's disease. Movement Disorders, 2016, 31, 95-102.	3.9	158
125	Activation of tyrosine kinase c-Abl contributes to Î±-synucleinâ€“induced neurodegeneration. Journal of Clinical Investigation, 2016, 126, 2970-2988.	8.2	133
126	Adult Conditional Knockout of PGC-1Î± Leads to Loss of Dopamine Neurons. ENeuro, 2016, 3, ENEURO.0183-16.2016.	1.9	87

#	ARTICLE	IF	CITATIONS
127	High-Content Genome-Wide RNAi Screen Reveals<i>CCR3</i>as a Key Mediator of Neuronal Cell Death. ENeuro, 2016, 3, ENEURO.0185-16.2016.	1.9	15
128	(Pathoâ€)physiological relevance of <scp>PINK</scp> 1â€dependent ubiquitin phosphorylation. EMBO Reports, 2015, 16, 1114-1130.	4.5	147
129	Lysosomal Enzyme Glucocerebrosidase Protects against AÎ²1-42 Oligomer-Induced Neurotoxicity. PLoS ONE, 2015, 10, e0143854.	2.5	12
130	<i>PARK10</i> is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology, 2015, 84, 972-980.	1.1	48
131	Cognitive profile of <i>LRRK2</i>â€related Parkinson's disease. Movement Disorders, 2015, 30, 728-733.	3.9	64
132	TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinsonâ€™s disease via CNTF. Brain, 2015, 138, 3610-3622.	7.6	95
133	Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11696-11701.	7.1	207
134	Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily. Human Molecular Genetics, 2014, 23, 2055-2077.	2.9	113
135	Abberant protein synthesis in G2019S LRRK2<i>Drosophila</i>Parkinson disease-related phenotypes. Fly, 2014, 8, 165-169.	1.7	19
136	<scp>M</scp>sp1/<scp>ATAD</scp>1 maintains mitochondrial function by facilitating the degradation of mislocalized tailâ€anchored proteins. EMBO Journal, 2014, 33, 1548-1564.	7.8	172
137	Protein Microarray Characterization of the S-Nitrosoproteome. Molecular and Cellular Proteomics, 2014, 13, 63-72.	3.8	56
138	LRRK2 pathobiology in Parkinson's disease. Journal of Neurochemistry, 2014, 131, 554-565.	3.9	131
139	Proneural Transcription Factor Atoh1 Drives Highly Efficient Differentiation of Human Pluripotent Stem Cells Into Dopaminergic Neurons. Stem Cells Translational Medicine, 2014, 3, 888-898.	3.3	35
140	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	9.0	312
141	Motor Neuron Death in ALS: Programmed by Astrocytes?. Neuron, 2014, 81, 961-963.	8.1	23
142	Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinsonâ€™s Disease. Cell, 2014, 157, 472-485.	28.9	239
143	Parkin and PINK1: much more than mitophagy. Trends in Neurosciences, 2014, 37, 315-324.	8.6	309
144	Parkin Plays a Role in Sporadic Parkinson's Disease. Neurodegenerative Diseases, 2014, 13, 69-71.	1.4	74

#	Article	IF	Citations
145	Early-onset Parkinson's disease due to PINK1 p.Q456X mutation â€“ Clinical and functional study. Parkinsonism and Related Disorders, 2014, 20, 1274-1278.	2.2	41
146	Parkinâ€independent mitophagy requires <scp>D</scp>rp1 and maintains the integrity of mammalian heart and brain. EMBO Journal, 2014, 33, 2798-2813.	7.8	361
147	Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10209-10214.	7.1	253
148	Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinsonâ€™s-like movement disorder. Nature Communications, 2014, 5, 4930.	12.8	118
149	Ganglioside Regulation of AMPA Receptor Trafficking. Journal of Neuroscience, 2014, 34, 13246-13258.	3.6	45
150	MiR-223 regulates the differentiation of immature neurons. Molecular and Cellular Therapies, 2014, 2, 18.	0.2	24
151	Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiology of Disease, 2014, 71, 345-358.	4.4	59
152	Parthanatos: mitochondrialâ€linked mechanisms and therapeutic opportunities. British Journal of Pharmacology, 2014, 171, 2000-2016.	5.4	432
153	Botch Is a Î³-Glutamyl Cyclotransferase that Deglycinates and Antagonizes Notch. Cell Reports, 2014, 7, 681-688.	6.4	29
154	Absence of <i>C9ORF72</i> expanded or intermediate repeats in autopsyâ€confirmed Parkinson's disease. Movement Disorders, 2014, 29, 827-830.	3.9	24
155	The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. Scientific Reports, 2014, 4, 4874.	3.3	188
156	Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nature Neuroscience, 2013, 16, 1392-1400.	14.8	182
157	Reprogramming cellular events by poly(ADP-ribose)-binding proteins. Molecular Aspects of Medicine, 2013, 34, 1066-1087.	6.4	141
158	Usp16: key controller of stem cells in Down syndrome. EMBO Journal, 2013, 32, 2788-2789.	7.8	6
159	New synaptic and molecular targets for neuroprotection in Parkinson's disease. Movement Disorders, 2013, 28, 51-60.	3.9	34
160	Sulfhydration mediates neuroprotective actions of parkin. Nature Communications, 2013, 4, 1626.	12.8	265
161	The interplay of microRNA and neuronal activity in health and disease. Frontiers in Cellular Neuroscience, 2013, 7, 136.	3.7	50
162	LRRK2 Affects Vesicle Trafficking, Neurotransmitter Extracellular Level and Membrane Receptor Localization. PLoS ONE, 2013, 8, e77198.	2.5	66

#	ARTICLE	IF	CITATIONS
163	Linked Clinical Trials â€“ The Development of New Clinical Learning Studies in Parkinson's Disease Using Screening of Multiple Prospective New Treatments. Journal of Parkinson's Disease, 2013, 3, 231-239.	2.8	35
164	Ironing out tau's role in parkinsonism. Nature Medicine, 2012, 18, 197-198.	30.7	13
165	ArfGAP1 Is a GTPase Activating Protein for LRRK2: Reciprocal Regulation of ArfGAP1 by LRRK2. Journal of Neuroscience, 2012, 32, 3877-3886.	3.6	92
166	Transcriptional responses to loss or gain of function of the leucine-rich repeat kinase 2 (LRRK2) gene uncover biological processes modulated by LRRK2 activity. Human Molecular Genetics, 2012, 21, 163-174.	2.9	34
167	Animal Models of Parkinson's Disease: Vertebrate Genetics. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009324-a009324.	6.2	99
168	Neurodegenerative phenotypes in an A53T Â-synuclein transgenic mouse model are independent of LRRK2. Human Molecular Genetics, 2012, 21, 2420-2431.	2.9	84
169	Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy. Journal of Neuroscience, 2012, 32, 16503-16509.	3.6	124
170	LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Biochemical Society Transactions, 2012, 40, 1074-1079.	3.4	21
171	MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18962-18967.	7.1	245
172	Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends in Pharmacological Sciences, 2012, 33, 365-373.	8.7	69
173	Botch Promotes Neurogenesis by Antagonizing Notch. Developmental Cell, 2012, 22, 707-720.	7.0	54
174	Metaâ€analysis of Parkinson's Disease: Identification of a novel locus, <i>RIT2</i>. Annals of Neurology, 2012, 71, 370-384.	5.3	264
175	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 141ra90.	12.4	444
176	Chemoproteomics-Based Design of Potent LRRK2-Selective Lead Compounds That Attenuate Parkinsonâ€™s Disease-Related Toxicity in Human Neurons. ACS Chemical Biology, 2011, 6, 1021-1028.	3.4	131
177	PARIS (ZNF746) Repression of PGC-1Î± Contributes to Neurodegeneration in Parkinson's Disease. Cell, 2011, 144, 689-702.	28.9	796
178	The AAA+ ATPase Thorase Regulates AMPA Receptor-Dependent Synaptic Plasticity and Behavior. Cell, 2011, 145, 284-299.	28.9	88
179	Poly(ADP-Ribose) (PAR) Binding to Apoptosis-Inducing Factor Is Critical for PAR Polymerase-1â€“Dependent Cell Death (Parthanatos). Science Signaling, 2011, 4, ra20.	3.6	360
180	MicroRNAs in Parkinson's disease. Journal of Chemical Neuroanatomy, 2011, 42, 127-130.	2.1	142

#	ARTICLE	IF	CITATIONS
181	Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2. PLoS ONE, 2011, 6, e18568.	2.5	338
182	Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nature Medicine, 2011, 17, 692-699.	30.7	190
183	Recent Advances in the Genetics of Parkinson's Disease. Annual Review of Genomics and Human Genetics, 2011, 12, 301-325.	6.2	355
184	A perfect â€œMatchâ€•for in vitro human disease modeling and autologous cell-based transplantation therapy: Generating genetically identical Parkinson's disease and control pluripotent stem cells by precise gene targeting. Movement Disorders, 2011, 26, 1804-1804.	3.9	0
185	Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14103-14108.	7.1	205
186	A Lysosomal Lair for a Pathogenic Protein Pair. Science Translational Medicine, 2011, 3, 91ps28.	12.4	11
187	Enhanced Autophagy from Chronic Toxicity of Iron and Mutant A53T Î±-Synuclein. Journal of Biological Chemistry, 2011, 286, 33380-33389.	3.4	82
188	Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Human Molecular Genetics, 2011, 20, 3933-3942.	2.9	120
189	Resistance to MPTP-Neurotoxicity in Î±-Synuclein Knockout Mice Is Complemented by Human Î±-Synuclein and Associated with Increased Î²-Synuclein and Akt Activation. PLoS ONE, 2011, 6, e16706.	2.5	57
190	Neuronal Activity Regulates Hippocampal miRNA Expression. PLoS ONE, 2011, 6, e25068.	2.5	48
191	The role of parkin in familial and sporadic Parkinson's disease. Movement Disorders, 2010, 25, S32-9.	3.9	309
192	Contributions of poly(ADPâ€•ribose) polymeraseâ€•1 and â€•2 to nuclear translocation of apoptosisâ€•inducing factor and injury from focal cerebral ischemia. Journal of Neurochemistry, 2010, 113, 1012-1022.	3.9	51
193	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000.	30.7	342
194	NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. Journal of Clinical Investigation, 2010, 120, 2446-2456.	8.2	42
195	Synphilin-1 attenuates neuronal degeneration in the A53T Â-synuclein transgenic mouse model. Human Molecular Genetics, 2010, 19, 2087-2098.	2.9	65
196	Reevaluation of Phosphorylation Sites in the Parkinson Disease-associated Leucine-rich Repeat Kinase 2. Journal of Biological Chemistry, 2010, 285, 29569-29576.	3.4	48
197	Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16691-16696.	7.1	241
198	PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 378-383.	7.1	1,415

#	ARTICLE	IF	CITATIONS
199	Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R215-R221.	1.8	18
200	GTPase Activity Plays a Key Role in the Pathobiology of LRRK2. PLoS Genetics, 2010, 6, e1000902.	3.5	177
201	The impact of genetic research on our understanding of Parkinsonâ€™s disease. Progress in Brain Research, 2010, 183, 21-41.	1.4	26
202	Genetic Animal Models of Parkinson's Disease. Neuron, 2010, 66, 646-661.	8.1	714
203	Functional Identification of Neuroprotective Molecules. PLoS ONE, 2010, 5, e15008.	2.5	31
204	S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4900-4905.	7.1	141
205	CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2897-2902.	7.1	195
206	Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila. Journal of Neuroscience, 2009, 29, 11257-11262.	3.6	193
207	Outer Mitochondrial Membrane Localization of Apoptosis-Inducing Factor: Mechanistic Implications for Release. ASN Neuro, 2009, 1, AN20090046.	2.7	69
208	Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radical Biology and Medicine, 2009, 47, 1049-1056.	2.9	55
209	Understanding microRNAs in neurodegeneration. Nature Reviews Neuroscience, 2009, 10, 837-841.	10.2	256
210	Calpain activation is not required for AIF translocation in PARPâ€•1â€•dependent cell death (parthanatos). Journal of Neurochemistry, 2009, 110, 687-696.	3.9	89
211	Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine). Journal of Neuroscience, 2009, 29, 15846-15850.	3.6	114
212	Poly(ADP-ribose) signals to mitochondrial AIF: A key event in parthanatos. Experimental Neurology, 2009, 218, 193-202.	4.1	327
213	SnapShot: Pathogenesis of Parkinson's Disease. Cell, 2009, 139, 440.e1-440.e2.	28.9	12
214	Revelations and revolutions in the understanding of Parkinsonâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 585-586.	3.8	3
215	Leucine-Rich Repeat Kinase 2 Expression Leads to Aggresome Formation That Is Not Associated With Î±-Synuclein Inclusions. Journal of Neuropathology and Experimental Neurology, 2009, 68, 785-796.	1.7	29
216	Abnormal Localization of Leucine-Rich Repeat Kinase 2 to the Endosomal-Lysosomal Compartment in Lewy Body Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 994-1005.	1.7	75

#	ARTICLE	IF	CITATIONS
217	Role of Tuberin in Neuronal Degeneration. Neurochemical Research, 2008, 33, 1113-1116.	3.3	10
218	Value of genetic models in understanding the cause and mechanisms of Parkinsonâ€™s disease. Current Neurology and Neuroscience Reports, 2008, 8, 288-296.	4.2	41
219	Morphometry of the human substantia nigra in ageing and Parkinsonâ€™s disease. Acta Neuropathologica, 2008, 115, 461-470.	7.7	150
220	Mitochondrial and Nuclear Cross Talk in Cell Death. Annals of the New York Academy of Sciences, 2008, 1147, 233-241.	3.8	284
221	Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nature Cell Biology, 2008, 10, 866-873.	10.3	353
222	Parkin mediates the degradationâ€independent ubiquitination of Hsp70. Journal of Neurochemistry, 2008, 105, 1806-1819.	3.9	101
223	Non-autonomous cell death in Parkinson's disease. Lancet Neurology, The, 2008, 7, 474-475.	10.2	16
224	Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Human Molecular Genetics, 2008, 17, 2570-2582.	2.9	143
225	Advances in Neuronal Cell Death 2007. Stroke, 2008, 39, 286-288.	2.0	36
226	Lysine 63-linked polyubiquitin potentially partners with p62 to promote the clearance of protein inclusions by autophagy. Autophagy, 2008, 4, 251-253.	9.1	54
227	The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2. Journal of Neuroscience, 2008, 28, 3384-3391.	3.6	178
228	Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Research, 2008, 36, 6959-6976.	14.5	359
229	Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Human Molecular Genetics, 2008, 17, 431-439.	2.9	379
230	Ataxia Telangiectasia Mutated (ATM) Signaling Network Is Modulated by a Novel Poly(ADP-ribose)-dependent Pathway in the Early Response to DNA-damaging Agents. Journal of Biological Chemistry, 2007, 282, 16441-16453.	3.4	225
231	The Roles of Kinases in Familial Parkinson's Disease. Journal of Neuroscience, 2007, 27, 11865-11868.	3.6	51
232	DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 14807-14812.	7.1	435
233	Relative Sensitivity of Parkin and Other Cysteine-containing Enzymes to Stress-induced Solubility Alterations. Journal of Biological Chemistry, 2007, 282, 12310-12318.	3.4	75
234	Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Human Molecular Genetics, 2007, 16, 223-232.	2.9	535

#	ARTICLE	IF	CITATIONS
235	Parkinson's disease genetic mutations increase cell susceptibility to stress: Mutant Î±-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiology of Aging, 2007, 28, 1709-1717.	3.1	53
236	A Hierarchical NGF Signaling Cascade Controls Ret-Dependent and Ret-Independent Events during Development of Nonpeptidergic DRG Neurons. Neuron, 2007, 54, 739-754.	8.1	225
237	Unraveling the role of defective genes in Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S248-S249.	2.2	10
238	Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. Journal of Neurochemistry, 2007, 100, 368-381.	3.9	101
239	Localization of Parkinsonâ€™s disease-associated LRRK2 in normal and pathological human brain. Brain Research, 2007, 1155, 208-219.	2.2	139
240	MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiology of Disease, 2007, 26, 312-322.	4.4	64
241	A Nitric Oxide Signaling Pathway Controls CREB-Mediated Gene Expression in Neurons. Molecular Cell, 2006, 21, 283-294.	9.7	211
242	Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases?. Neurobiology of Aging, 2006, 27, 524-529.	3.1	130
243	Parkin Blushed by PINK1. Neuron, 2006, 50, 527-529.	8.1	39
244	Diagnosis and treatment of Parkinson disease: molecules to medicine. Journal of Clinical Investigation, 2006, 116, 1744-1754.	8.2	538
245	Taming the clot-buster tPA. Nature Medicine, 2006, 12, 993-994.	30.7	8
246	Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience, 2006, 9, 1231-1233.	14.8	587
247	Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3887-3889.	7.1	222
248	Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18314-18319.	7.1	655
249	Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate. Journal of Biological Chemistry, 2006, 281, 16193-16196.	3.4	91
250	Inclusion Body Formation and Neurodegeneration Are Parkin Independent in a Mouse Model of Â-Synucleinopathy. Journal of Neuroscience, 2006, 26, 3685-3696.	3.6	86
251	Poly(ADP-ribose) (PAR) polymer is a death signal. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 18308-18313.	7.1	572
252	Lessons from Drosophila Models of DJ-1 Deficiency. Science of Aging Knowledge Environment: SAGE KE, 2006, 2006, pe2-pe2.	0.8	27

#	Article	IF	Citations
253	Failures and Successes of Clinical Trials for Parkinson Disease Treatments. Retina, 2005, 25, S75-S77.	1.7	2
254	Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations. Journal of Neurochemistry, 2005, 93, 422-431.	3.9	110
255	Neurotoxicity and behavioral deficits associated with Septinâ€ƒ5 accumulation in dopaminergic neurons. Journal of Neurochemistry, 2005, 94, 1040-1053.	3.9	65
256	The involvement of nitric oxide in the enhanced expression of Î¼ -opioid receptors during intestinal inflammation in mice. British Journal of Pharmacology, 2005, 145, 758-766.	5.4	29
257	The role of nitric oxide and PARP in neuronal cell death. , 2005, , 146-156.		0
258	Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Human Molecular Genetics, 2005, 14, 2571-2586.	2.9	200
259	Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Human Molecular Genetics, 2005, 14, 71-84.	2.9	231
260	Bcl-x Is Required for Proper Development of the Mouse Substantia Nigra. Journal of Neuroscience, 2005, 25, 6721-6728.	3.6	140
261	Sâ€Nitrosylation in Parkinson's Disease and Related Neurodegenerative Disorders. Methods in Enzymology, 2005, 396, 139-150.	1.0	38
262	Identification and Evaluation of NOâ€Regulated Genes by Differential Analysis of Primary cDNA Library Expression (DAzLE). Methods in Enzymology, 2005, 396, 359-368.	1.0	1
263	Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18676-18681.	7.1	390
264	Parkin Mediates Nonclassical, Proteasomal-Independent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation. Journal of Neuroscience, 2005, 25, 2002-2009.	3.6	489
265	Aggregation promoting C-terminal truncation of Î±-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2162-2167.	7.1	405
266	Accumulation of the Authentic Parkin Substrate Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell Death. Journal of Neuroscience, 2005, 25, 7968-7978.	3.6	221
267	The Road to Survival Goes through PARG. Cell Cycle, 2005, 4, 397-399.	2.6	21
268	Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Human Molecular Genetics, 2005, 14, 3885-3897.	2.9	201
269	Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Human Molecular Genetics, 2005, 14, 2063-2073.	2.9	381
270	Â-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells. Journal of Neuroscience, 2005, 25, 5544-5552.	3.6	237

#	ARTICLE	IF	CITATIONS
271	MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE. Annual Review of Neuroscience, 2005, 28, 57-87.	10.7	1,111
272	Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16842-16847.	7.1	1,084
273	Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease. Molecular Brain Research, 2005, 134, 103-108.	2.3	71
274	The 350-fold compacted Fugu parkin gene is structurally and functionally similar to human Parkin. Gene, 2005, 346, 97-104.	2.2	6
275	To die or grow: Parkinson's disease and cancer. Trends in Neurosciences, 2005, 28, 348-352.	8.6	110
276	AÎ² deposition is associated with enhanced cortical Î±-synuclein lesions in Lewy body diseases. Neurobiology of Aging, 2005, 26, 1183-1192.	3.1	200
277	Recent advances in our understanding of Parkinson's disease. Drug Discovery Today Disease Mechanisms, 2005, 2, 427-433.	0.8	14
278	Mediation of cell death by poly(ADP-ribose) polymerase-1. Pharmacological Research, 2005, 52, 5-14.	7.1	218
279	Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Human Molecular Genetics, 2005, 14, 3801-3811.	2.9	321
280	Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 17699-17704.	7.1	285
281	Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10744-10749.	7.1	317
282	Identification of calcium- and nitric oxide-regulated genes by differential analysis of library expression (DAzLE). Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 647-652.	7.1	32
283	Identification and analysis of plasticity-induced late-response genes. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2145-2150.	7.1	57
284	PARPâ€1 gene disruption in mice preferentially protects males from perinatal brain injury. Journal of Neurochemistry, 2004, 90, 1068-1075.	3.9	266
285	Deadly Conversations: Nuclear-Mitochondrial Cross-Talk. Journal of Bioenergetics and Biomembranes, 2004, 36, 287-294.	2.3	169
286	Parkin-associated Parkinsonâ€™s disease. Cell and Tissue Research, 2004, 318, 175-184.	2.9	126
287	S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function. Science, 2004, 304, 1328-1331.	12.6	736
288	Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Annals of Medicine, 2004, 36, 315-320.	3.8	123

#	ARTICLE	IF	CITATIONS
289	P3-228 Chip and HSP70 regulate tau ubiquitination, degradation and aggregation. Neurobiology of Aging, 2004, 25, S419-S420.	3.1	2
290	Apoptosis-Inducing Factor Substitutes for Caspase Executioners in NMDA-Triggered Excitotoxic Neuronal Death. Journal of Neuroscience, 2004, 24, 10963-10973.	3.6	258
291	Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends in Pharmacological Sciences, 2004, 25, 259-264.	8.7	423
292	Parkin and Hsp70 Sacked by BAG5. Neuron, 2004, 44, 899-901.	8.1	23
293	CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Human Molecular Genetics, 2004, 13, 703-714.	2.9	613
294	Astroglia Induce Cytotoxic Effects on Brain Tumors via a Nitric Oxide-Dependent Pathway Both in Vitro and in Vivo. Neurosurgery, 2004, 54, 1231-1238.	1.1	13
295	What have Genetically Engineered Mice Taught Us About Ischemic Injury?. Current Molecular Medicine, 2004, 4, 207-225.	1.3	14
296	Role for the Ubiquitin-Proteasome System in Parkinson's Disease and Other Neurodegenerative Brain Amyloidoses. NeuroMolecular Medicine, 2003, 4, 95-108.	3.4	50
297	Genetics of Parkinson's disease: What do mutations in DJ-1 tell us?. Annals of Neurology, 2003, 54, 281-282.	5.3	14
298	A missense mutation (L166P) in DJâ€1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homoâ€oligomerization. Journal of Neurochemistry, 2003, 87, 1558-1567.	3.9	198
299	Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiology of Disease, 2003, 14, 303-317.	4.4	185
300	Caught in the Act. Neuron, 2003, 40, 453-456.	8.1	184
301	BAK Alters Neuronal Excitability and Can Switch from Anti- to Pro-Death Function during Postnatal Development. Developmental Cell, 2003, 4, 575-585.	7.0	101
302	Molecular Pathways of Neurodegeneration in Parkinson's Disease. Science, 2003, 302, 819-822.	12.6	1,530
303	37-kDa Laminin Receptor Precursor Modulates Cytotoxic Necrotizing Factor 1â€“mediated RhoA Activation and Bacterial Uptake. Journal of Biological Chemistry, 2003, 278, 16857-16862.	3.4	106
304	Novel Monoclonal Antibodies Demonstrate Biochemical Variation of Brain Parkin with Age. Journal of Biological Chemistry, 2003, 278, 48120-48128.	3.4	140
305	Nitric Oxide Protects Cardiac Sarcolemmal Membrane Enzyme Function and Ion Active Transport against Ischemia-induced Inactivation. Journal of Biological Chemistry, 2003, 278, 41798-41803.	3.4	40
306	Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an Expanded Polyglutamine Repeat, Increases Cellular Toxicity. Journal of Biological Chemistry, 2003, 278, 13047-13055.	3.4	78

#	Article	IF	Citations
307	The Cast of Molecular Characters in Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 80-92.	3.8	35
308	Apoptosis Inducing Factor and PARPâ€Mediated Injury in the MPTP Mouse Model of Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 132-139.	3.8	112
309	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. Journal of Clinical Investigation, 2003, 111, 145-151.	8.2	91
310	Rare genetic mutations shed light on the pathogenesis of Parkinson disease. Journal of Clinical Investigation, 2003, 111, 145-151.	8.2	175
311	Human Î±-synuclein-harboring familial Parkinson's disease-linked Ala-53 â†' Thr mutation causes neurodegenerative disease with Î±-synuclein aggregation in transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8968-8973.	7.1	730
312	The Orphan Nuclear Receptor, Steroidogenic Factor 1, Regulates Neuronal Nitric Oxide Synthase Gene Expression in Pituitary Gonadotropes. Molecular Endocrinology, 2002, 16, 2828-2839.	3.7	27
313	Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. Journal of Cell Biology, 2002, 158, 507-517.	5.2	434
314	Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor. Science, 2002, 297, 259-263.	12.6	1,671
315	Preconditioning-mediated neuroprotection through erythropoietin?. Lancet, The, 2002, 359, 96-97.	13.7	54
316	Lack of nitric oxide synthase depresses ion transporting enzyme function in cardiac muscle. Biochemical and Biophysical Research Communications, 2002, 294, 1030-1035.	2.1	35
317	Animal Models of PD. Neuron, 2002, 35, 219-222.	8.1	131
318	Mechanisms of ischemic tolerance. , 2002, , 58-71.		0
319	Poly(ADP-Ribose) Polymerase Impairs Early and Long-Term Experimental Stroke Recovery. Stroke, 2002, 33, 1101-1106.	2.0	123
320	The genetics of Parkinsonâ€™s disease. Current Neurology and Neuroscience Reports, 2002, 2, 439-446.	4.2	27
321	A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. Journal of Neurochemistry, 2002, 83, 186-192.	3.9	75
322	CREB family transcription factors inhibit neuronal suicide. Nature Medicine, 2002, 8, 450-451.	30.7	51
323	Neuroprotective and neurorestorative strategies for Parkinson's disease. Nature Neuroscience, 2002, 5, 1058-1061.	14.8	152
324	Gene therapy to the rescue in Parkinson's disease. Trends in Pharmacological Sciences, 2001, 22, 103-105.	8.7	4

#	ARTICLE	IF	CITATIONS
325	The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends in Neurosciences, 2001, 24, 7-14.	8.6	161
326	Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity. Science, 2001, 291, 2423-2428.	12.6	1,035
327	Reduction of functional N-methyl-d-aspartate receptors in neurons by RNase P-mediated cleavage of the NR1 mRNA. Journal of Neurochemistry, 2001, 76, 1386-1394.	3.9	8
328	Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. European Journal of Neuroscience, 2001, 13, 1683-1693.	2.6	87
329	Neuroimmunophilins: Novel neuroprotective and neuroregenerative targets. Annals of Neurology, 2001, 50, 6-16.	5.3	85
330	Parkin ubiquitinates the Î±-synucleinâ€“interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nature Medicine, 2001, 7, 1144-1150.	30.7	710
331	Parkin: clinical aspects and neurobiology. Clinical Neuroscience Research, 2001, 1, 467-482.	0.8	15
332	Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics, 2001, 10, 919-926.	2.9	442
333	NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase. Journal of Neuroscience, 2000, 20, 8005-8011.	3.6	206
334	Stroke Outcome in Double-Mutant Antioxidant Transgenic Mice. Stroke, 2000, 31, 2685-2691.	2.0	44
335	Parkinson's disease: clinical manifestations and treatment. International Review of Psychiatry, 2000, 12, 263-269.	2.8	5
336	Oxidative Stress and Genetics in the Pathogenesis of Parkinson's Disease. Neurobiology of Disease, 2000, 7, 240-250.	4.4	397
337	Reply: a new look at the pathogenesis of Parkinsonâ€™s disease. Trends in Pharmacological Sciences, 2000, 21, 165.	8.7	22
338	Neuronal ischaemic preconditioning. Trends in Pharmacological Sciences, 2000, 21, 423-424.	8.7	55
339	New Animal Models for Parkinson's Disease. Cell, 2000, 101, 115-118.	28.9	92
340	Mechanisms and Structural Determinants of HIV-1 Coat Protein, gp41-Induced Neurotoxicity. Journal of Neuroscience, 1999, 19, 64-71.	3.6	71
341	Circadian Locomotor Analysis of Male Mice Lacking the Gene for Neuronal Nitric Oxide Synthase (nNOSâ€“/â€“). Journal of Biological Rhythms, 1999, 14, 20-27.	2.6	29
342	Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine, 1999, 5, 1403-1409.	30.7	1,007

#	ARTICLE	IF	CITATIONS
343	Synphilin-1 associates with Î±-synuclein and promotes the formation of cytosolic inclusions. Nature Genetics, 1999, 22, 110-114.	21.4	473
344	Overview of the Pathway and Functions of Nitric Oxide. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 1999, 00, Unit 10.1.	1.1	0
345	Nuclear Targeting of Mutant Huntingtin Increases Toxicity. Molecular and Cellular Neurosciences, 1999, 14, 121-128.	2.2	177
346	Histochemical Analysis of Nitric Oxide Synthase by NADPH Diaphorase Staining. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 1999, 1, Unit 10.6.	1.1	7
347	Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats. Stroke, 1999, 30, 1279-1285.	2.0	56
348	Free Radicals as Mediators of Neuronal Injury. Cellular and Molecular Neurobiology, 1998, 18, 667-682.	3.3	208
349	Chapter 1 Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Progress in Brain Research, 1998, 118, 3-11.	1.4	110
350	Chapter 15 Nitric oxide in neurodegeneration. Progress in Brain Research, 1998, 118, 215-229.	1.4	336
351	Nitric Oxide: Diverse Actions in the Central and Peripheral Nervous Systems. Neuroscientist, 1998, 4, 96-112.	3.5	20
352	NMDAR1 Glutamate Receptor Subunit Isoforms in Neostriatal, Neocortical, and Hippocampal Nitric Oxide Synthase Neurons. Journal of Neuroscience, 1998, 18, 1725-1734.	3.6	71
353	Manganese Superoxide Dismutase Protects nNOS Neurons from NMDA and Nitric Oxide-Mediated Neurotoxicity. Journal of Neuroscience, 1998, 18, 2040-2055.	3.6	258
354	Differential Susceptibility to Neurotoxicity Mediated by Neurotrophins and Neuronal Nitric Oxide Synthase. Journal of Neuroscience, 1997, 17, 4633-4641.	3.6	98
355	Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nature Medicine, 1997, 3, 421-428.	30.7	346
356	Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans. Nature Medicine, 1997, 3, 571-574.	30.7	138
357	Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nature Medicine, 1997, 3, 1089-1095.	30.7	1,002
358	NMDA-R1 subunit of the cerebral cortex co-localizes with neuronal nitric oxide synthase at pre- and postsynaptic sites and in spines. Brain Research, 1997, 750, 25-40.	2.2	102
359	Aggressive behavior in male mice lacking the gene for neuronal nitric oxide synthase requires testosterone. Brain Research, 1997, 769, 66-70.	2.2	62
360	Effects of Nitric Oxide on Neuroendocrine Function and Behavior. Frontiers in Neuroendocrinology, 1997, 18, 463-491.	5.2	107

#	Article	IF	Citations
361	Nitric Oxide Synthase in Models of Focal Ischemia. Stroke, 1997, 28, 1283-1288.	2.0	578
362	NITRIC OXIDE SYNTHASE: Role as a Transmitter/Mediator in the Brain and Endocrine System. Annual Review of Medicine, 1996, 47, 219-227.	12.2	141
363	Nitric oxide neurotoxicity. Journal of Chemical Neuroanatomy, 1996, 10, 179-190.	2.1	460
364	NITRIC OXIDE ACTIONS IN NEUROCHEMISTRY. Neurochemistry International, 1996, 29, 97-110.	3.8	174
365	Nitric Oxide Synthase Inhibitors. CNS Drugs, 1996, 6, 351-357.	5.9	10
366	Generation of isoform-specific antibodies to nitric oxide synthases. Methods in Enzymology, 1996, 268, 349-358.	1.0	4
367	Nitric oxide synthase (NOS) in schizophrenia. Molecular and Chemical Neuropathology, 1996, 27, 275-284.	1.0	71
368	Immunosuppressants, immunophilins, and the nervous system. Annals of Neurology, 1996, 40, 559-560.	5.3	31
369	Loss of nitric oxide synthase immunoreactivity in cerebral vasospasm. Journal of Neurosurgery, 1996, 84, 648-654.	1.6	138
370	Neurobiology of Nitric Oxide. Critical Reviews in Neurobiology, 1996, 10, 291-316.	3.1	255
371	Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Annals of Neurology, 1995, 37, 115-118.	5.3	68
372	Effects of Central Inhibition of Nitric Oxide Synthase on Focal Cerebral Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 1995, 15, 779-786.	4.3	34
373	Behavioural abnormalities in male mice lacking neuronal nitric oxide synthase. Nature, 1995, 378, 383-386.	27.8	606
374	REVIEW â– : Nitric Oxide: Actions and Pathological Roles. Neuroscientist, 1995, 1, 7-18.	3.5	100
375	Physiological and Toxicological Actions of Nitric Oxide in the Central Nervous System. Advances in Pharmacology, 1995, 34, 323-342.	2.0	62
376	Widespread expression of Huntington's disease gene (IT15) protein product. Neuron, 1995, 14, 1065-1074.	8.1	485
377	Chapter 30 Nitric oxide: cellular regulation and neuronal injury. Progress in Brain Research, 1994, 103, 365-369.	1.4	72
378	Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Annals of Neurology, 1994, 36, 778-786.	5.3	527

#	ARTICLE	IF	CITATIONS
379	Nitric oxide mediates the formation of synaptic connections in developing and regenerating olfactory receptor neurons. Neuron, 1994, 13, 289-299.	8.1	232
380	gp120 neurotoxicity in primary cortical cultures. Advances in Neuroimmunology, 1994, 4, 167-173.	1.8	24
381	Secondary mechanisms in neuronal trauma. Current Opinion in Neurology, 1994, 7, 510-516.	3.6	141
382	Molecular Mechanisms of Nitric Oxide Actions in the Brain^a. Annals of the New York Academy of Sciences, 1994, 738, 76-85.	3.8	103
383	Reactive nitrogen intermediates: Effector molecules of immune-mediated inflammatory nervous system disorders?. Annals of Neurology, 1993, 33, 422-422.	5.3	0
384	Possible Origins and Distribution of Immunoreactive Nitric Oxide Synthase-Containing Nerve Fibers in Cerebral Arteries. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 70-79.	4.3	370
385	Neurotransmitter release regulated by nitric oxide in PC-12 cells and brain synaptosomes. Current Biology, 1993, 3, 749-754.	3.9	108
386	Enhanced expression of nitric oxide synthase by rat retina following pterygopalatine parasympathetic denervation. Brain Research, 1993, 631, 83-88.	2.2	48
387	Targeted disruption of the neuronal nitric oxide synthase gene. Cell, 1993, 75, 1273-1286.	28.9	1,323
388	High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature, 1992, 358, 584-587.	27.8	338
389	Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease. Annals of Neurology, 1992, 32, 818-820.	5.3	177
390	Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants. Brain Research, 1991, 540, 145-152.	2.2	22
391	Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron, 1991, 7, 615-624.	8.1	1,390
392	Thrombotic microangiopathy isolated to the central nervous system. Annals of Neurology, 1991, 30, 843-846.	5.3	2
393	Muscarinic and dopaminergic receptor subtypes on striatal cholinergic interneurons. Brain Research Bulletin, 1990, 25, 903-912.	3.0	36
394	Decreased beta-adrenergic receptors in rat brain after chronic administration of the selective serotonin uptake inhibitor fluoxetine. Psychopharmacology, 1988, 94, 141-143.	3.1	61
395	Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. Life Sciences, 1988, 42, 1933-1939.	4.3	77
396	Localization of nigrostriatal dopamine receptor subtypes and adenylate cyclase. Brain Research Bulletin, 1988, 20, 447-459.	3.0	69

#	Article	IF	Citations
397	Presynaptic and postsynaptic D1 dopamine receptors in the nigrostriatal system of the rat brain: a quantitative autoradiographic study using the selective D1 antagonist [3H]SCH 23390. Brain Research, 1987, 408, 205-209.	2.2	84
398	Chronic administration of sertraline, a selective serotonin uptake inhibitor, decreased the density of Î²-adrenergic receptors in rat frontoparietal cortex. Brain Research, 1987, 421, 377-381.	2.2	29
399	Evidence that [3H]forskolin binding in the substantia nigra is intrinsic to a striatal-nigral projection: An autoradiographic study of rat brain. Neuroscience Letters, 1987, 73, 114-118.	2.1	27
400	Autoradiographic Evidence of [3H]SCH 23390 Binding Site; in Human Prefrontal Cortex (Brodmann's) Tj ETQq0 0 0 rgBT /Overlock 10 T	3.9	34
401	Quantitative autoradiographic evidence for axonal transport of imipramine receptors in the central nervous system of the rat. Neuroscience Letters, 1985, 55, 261-266.	2.1	32